Targeting HOX/PBX dimers in cancer

Morgan, Richard ORCID: https://orcid.org/0000-0002-8721-4479, El-Tanani, Mohamed, Hunter, Keith, Harrington, Kevin and Pandha, Hardev (2017) Targeting HOX/PBX dimers in cancer. Oncotarget, 8 (19). pp. 32322-32331.

[thumbnail of HOXPBX review Oncotarget 2017 RMorgan.pdf]
Preview
PDF
HOXPBX review Oncotarget 2017 RMorgan.pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

The HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also dysregulated in a wide range of solid and haematological malignancies and have a predominantly pro-oncogenic function. A key mode of transcriptional regulation by HOX and PBX proteins is through their interaction as a heterodimer or larger complex that enhances their binding affinity and specificity for DNA, and there is growing evidence that this interaction is a potential therapeutic target in malignancies that include prostate, breast, renal, ovarian and lung cancer, melanoma, myeloma, and acute myeloid leukaemia. This review summarizes the roles of HOX and PBX genes in cancer and assesses the therapeutic potential of HOX/PBX dimer inhibition, including the availability of biomarkers for its application in precision medicine.

Item Type: Article
Identifier: doi10.18632/oncotarget.15971
Keywords: HOX, PBX, HXR9, targeted therapy, biomarker
Subjects: Natural sciences > Cell and molecular biology
Related URLs:
Depositing User: Richard Morgan
Date Deposited: 08 Jul 2020 13:20
Last Modified: 06 Feb 2024 16:03
URI: https://repository.uwl.ac.uk/id/eprint/7102

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item

Menu